110 related articles for article (PubMed ID: 20214633)
1. Cells with minimal expression of the JAK/STAT pathway related proteins STAT5a and the prolactin receptor: evidence of an alternate prolactin receptor isoform in breast disease.
Bratthauer GL; Stamatakos MD; Vinh TN
Protein Pept Lett; 2010 Jan; 17(1):104-8. PubMed ID: 20214633
[TBL] [Abstract][Full Text] [Related]
2. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
[TBL] [Abstract][Full Text] [Related]
3. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
4. Nectin-4 co-stimulates the prolactin receptor by interacting with SOCS1 and inhibiting its activity on the JAK2-STAT5a signaling pathway.
Maruoka M; Kedashiro S; Ueda Y; Mizutani K; Takai Y
J Biol Chem; 2017 Apr; 292(17):6895-6909. PubMed ID: 28258213
[TBL] [Abstract][Full Text] [Related]
5. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition.
Sultan AS; Brim H; Sherif ZA
Cancer Sci; 2008 Feb; 99(2):272-9. PubMed ID: 18271926
[TBL] [Abstract][Full Text] [Related]
6. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
7. Reversed Expression of the JAK/STAT Pathway Related Proteins Prolactin Receptor and STAT5a in Normal and Abnormal Breast Epithelial Cells.
Bratthauer GL; Strauss BL; Barner R
Breast Cancer (Auckl); 2008; 1():7-14. PubMed ID: 21655368
[TBL] [Abstract][Full Text] [Related]
8. HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription.
Fiorillo AA; Medler TR; Feeney YB; Liu Y; Tommerdahl KL; Clevenger CV
Mol Endocrinol; 2011 Sep; 25(9):1550-64. PubMed ID: 21816901
[TBL] [Abstract][Full Text] [Related]
9. Prolactin receptor in primary hyperparathyroidism--expression, functionality and clinical correlations.
Haglund F; Lu M; Vukojević V; Nilsson IL; Andreasson A; Džabić M; Bränström R; Höög A; Juhlin CC; Larsson C
PLoS One; 2012; 7(5):e36448. PubMed ID: 22606260
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain.
Kline JB; Rycyzyn MA; Clevenger CV
Mol Endocrinol; 2002 Oct; 16(10):2310-22. PubMed ID: 12351696
[TBL] [Abstract][Full Text] [Related]
11. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
12. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling.
García-Martínez JM; Calcabrini A; González L; Martín-Forero E; Agulló-Ortuño MT; Simon V; Watkin H; Anderson SM; Roche S; Martín-Pérez J
Cell Signal; 2010 Mar; 22(3):415-26. PubMed ID: 19892015
[TBL] [Abstract][Full Text] [Related]
13. Connections between prolactin and ovarian cancer.
Alkharusi A; AlMuslahi A; AlBalushi N; AlAjmi R; AlRawahi S; AlFarqani A; Norstedt G; Zadjali F
PLoS One; 2021; 16(8):e0255701. PubMed ID: 34358244
[TBL] [Abstract][Full Text] [Related]
14. Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies.
Ginsburg E; Alexander S; Lieber S; Tarplin S; Jenkins L; Pang L; Heger CD; Goldsmith P; Vonderhaar BK
BMC Cancer; 2010 Dec; 10():678. PubMed ID: 21144038
[TBL] [Abstract][Full Text] [Related]
15. SOCS-1, -2, -3: selective targets and functions downstream of the prolactin receptor.
Tomic S; Chughtai N; Ali S
Mol Cell Endocrinol; 1999 Dec; 158(1-2):45-54. PubMed ID: 10630404
[TBL] [Abstract][Full Text] [Related]
16. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
Bogorad RL; Courtillot C; Mestayer C; Bernichtein S; Harutyunyan L; Jomain JB; Bachelot A; Kuttenn F; Kelly PA; Goffin V; Touraine P;
Proc Natl Acad Sci U S A; 2008 Sep; 105(38):14533-8. PubMed ID: 18779591
[TBL] [Abstract][Full Text] [Related]
17. Impaired hypothalamic leptin sensitivity in pseudopregnant rats treated with chronic prolactin to mimic pregnancy.
Augustine RA; Knowles PJ; Khant Aung Z; Grattan DR; Ladyman SR
J Neuroendocrinol; 2019 Sep; 31(9):e12702. PubMed ID: 30803074
[TBL] [Abstract][Full Text] [Related]
18. Amplification of the prolactin receptor gene in mammary lobular neoplasia.
Tran-Thanh D; Arneson NC; Pintilie M; Deliallisi A; Warren KS; Bane A; Done SJ
Breast Cancer Res Treat; 2011 Jul; 128(1):31-40. PubMed ID: 20658264
[TBL] [Abstract][Full Text] [Related]
19. Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer.
Tan D; Tang P; Huang J; Zhang J; Zhou W; Walker AM
Chin Med J (Engl); 2014; 127(6):1077-83. PubMed ID: 24622438
[TBL] [Abstract][Full Text] [Related]
20. Association of prolactin receptor (PRLR) variants with prolactinomas.
Gorvin CM; Newey PJ; Rogers A; Stokes V; Neville MJ; Lines KE; Ntali G; Lees P; Morrison PJ; Singhellakis PN; Malandrinou FC; Karavitaki N; Grossman AB; Karpe F; Thakker RV
Hum Mol Genet; 2019 Mar; 28(6):1023-1037. PubMed ID: 30445560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
